MA54925A - Compositions pour le traitement de troubles acido-basiques - Google Patents

Compositions pour le traitement de troubles acido-basiques

Info

Publication number
MA54925A
MA54925A MA054925A MA54925A MA54925A MA 54925 A MA54925 A MA 54925A MA 054925 A MA054925 A MA 054925A MA 54925 A MA54925 A MA 54925A MA 54925 A MA54925 A MA 54925A
Authority
MA
Morocco
Prior art keywords
compositions
acid
treatment
based disorders
disorders
Prior art date
Application number
MA054925A
Other languages
English (en)
Inventor
Kalpesh N Biyani
Jerry M Buysse
Eric F Connor
Michael J Cope
Randi K Gbur
Matthew J Kade
Paul H Kierstead
Gerrit Klaerner
Son H Nguyen
Scott M Tabakman
Original Assignee
Tricida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tricida Inc filed Critical Tricida Inc
Publication of MA54925A publication Critical patent/MA54925A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/02—Alkylation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F226/04—Diallylamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
MA054925A 2016-05-06 2017-05-05 Compositions pour le traitement de troubles acido-basiques MA54925A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662333059P 2016-05-06 2016-05-06
US201662350686P 2016-06-15 2016-06-15
US201662408885P 2016-10-17 2016-10-17
US201662414966P 2016-10-31 2016-10-31

Publications (1)

Publication Number Publication Date
MA54925A true MA54925A (fr) 2021-12-22

Family

ID=59315687

Family Applications (3)

Application Number Title Priority Date Filing Date
MA044875A MA44875A (fr) 2016-05-06 2017-05-05 Compositions pour le traitement de troubles acido-basiques
MA054925A MA54925A (fr) 2016-05-06 2017-05-05 Compositions pour le traitement de troubles acido-basiques
MA044886A MA44886A (fr) 2016-05-06 2017-05-05 Compositions et méthode pour traiter des troubles acide-base

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA044875A MA44875A (fr) 2016-05-06 2017-05-05 Compositions pour le traitement de troubles acido-basiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA044886A MA44886A (fr) 2016-05-06 2017-05-05 Compositions et méthode pour traiter des troubles acide-base

Country Status (15)

Country Link
US (6) US20200054669A1 (fr)
EP (3) EP3831395A1 (fr)
JP (3) JP7071284B2 (fr)
KR (1) KR102655774B1 (fr)
CN (2) CN109414453B (fr)
AU (3) AU2017261337A1 (fr)
BR (1) BR112018072714A2 (fr)
CA (1) CA3023264A1 (fr)
IL (2) IL262660B2 (fr)
MA (3) MA44875A (fr)
MX (1) MX2018013476A (fr)
MY (1) MY197091A (fr)
RU (1) RU2018142943A (fr)
SG (1) SG11201809605PA (fr)
WO (3) WO2017193064A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2834485T3 (es) 2013-06-05 2021-06-17 Tricida Inc Polímeros de unión a protones para administración oral
MA41150B1 (fr) 2014-12-10 2020-06-30 Tricida Inc Polymères de liaison aux protons pour administration orale
MA44875A (fr) * 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
EP3698798A4 (fr) * 2017-10-16 2020-12-23 FUJIFILM Corporation Agent thérapeutique contre l'hyperphosphatémie, et particules
IL273960B2 (en) 2017-11-03 2025-08-01 Tricida Inc Nonabsorable compositions for use in treating or preventing metabolic acidosis
WO2019090177A1 (fr) * 2017-11-03 2019-05-09 Tricida, Inc. Méthode de traitement de troubles de type acide-base
MA51628A (fr) * 2018-06-04 2021-03-17 Tricida Inc Méthode de traitement de troubles de l'équilibre acido-basique
WO2019236639A1 (fr) * 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement des troubles de l'équilibre acido-basique
RS67452B1 (sr) 2021-03-01 2025-12-31 Renosis Inc Umrežene poli(alilamin)ske polimerne farmaceutske kompozicije
JP7828096B2 (ja) 2021-03-01 2026-03-11 トリシダ・インコーポレイテッド 架橋ポリ（アリルアミン）ポリマー医薬組成物
WO2023109825A1 (fr) * 2021-12-14 2023-06-22 上海石趣医药科技有限公司 Utilisation d'oxyde d'argent et/ou d'hydrate de celui-ci dans la préparation d'un médicament
WO2023109826A1 (fr) * 2021-12-14 2023-06-22 上海石趣医药科技有限公司 Utilisation de carbonate d'argent dans la préparation d'un médicament

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
EP0786993B1 (fr) 1994-10-17 2002-06-05 Peter W. Stacpoole Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et leur utilisation dans le traitement de troubles metaboliques et cardiovasculaires
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5753706A (en) 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
AU2682499A (en) 1998-02-17 1999-08-30 Dimitri R. Kioussis Anion binding polymers and the use thereof
US6485703B1 (en) 1998-07-31 2002-11-26 The Texas A&M University System Compositions and methods for analyte detection
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB9927088D0 (en) 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
WO2001066607A1 (fr) 2000-03-09 2001-09-13 Hisamitsu Pharmaceutical Co., Inc. Resine echangeuse d'anions reticulee ou sel de celle-ci et adsorbant phosphoreux la contenant
US20040059065A1 (en) 2000-03-09 2004-03-25 Takeshi Goto Crosslinked anion-exchange resin or salt thereof
WO2001068106A1 (fr) 2000-03-13 2001-09-20 Hisamitsu Pharmaceutical Co., Inc. Prophylactiques et/ou remedes pour hyperphosphatemie
JP2002028737A (ja) 2000-07-07 2002-01-29 Fujitsu Ltd プレス打ち抜き加工方法及びプレス打ち抜き加工装置
AT409630B (de) * 2000-12-13 2002-09-25 Dsm Fine Chem Austria Gmbh Alkylierung von n-bzw. amino- oder ammoniumgruppen haltigen, vernetzten polymeren
BR0209133A (pt) 2001-04-18 2004-06-15 Genzyme Corp Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue
KR20040018357A (ko) 2001-04-18 2004-03-03 젠자임 코포레이션 저염 형태의 폴리알릴아민
CN1274668C (zh) 2002-03-11 2006-09-13 诺瓦提斯公司 那格列奈的盐
US20070135335A1 (en) 2003-02-10 2007-06-14 Autogen Research Pty Ltd. Therapeutic molecules
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7767768B2 (en) 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
AU2004311849B2 (en) 2003-12-31 2009-04-02 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US20080248012A1 (en) 2004-01-29 2008-10-09 Keio University Erythrocyte Function Modifying Substance
KR101228233B1 (ko) 2004-03-30 2013-01-31 리립사, 인크. 이온 결합 중합체 및 이의 용도
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
EP1771191B1 (fr) 2004-07-19 2014-03-12 N.V. Nutricia Preparation pour l'utilisation de l'aspartate et de la vitamine b12 ou biotine afin de reguler les corps cetoniques
DE102004035808A1 (de) 2004-07-21 2006-03-16 Kasch, Helmut, Dr. Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20070293429A1 (en) 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
US20080214440A1 (en) 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
EP1898922A4 (fr) 2005-07-04 2012-03-14 Ramu Krishnan Medicament ou composes pharmaceutiques ameliores et preparation associee
EP2594551B1 (fr) 2005-08-18 2025-02-19 Panion & BF Biotech Inc. Utilisations des composés organiques ferriques de qualité pharmaceutique
JP2009507019A (ja) 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
BRPI0616603A2 (pt) 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma
DE112006002618T5 (de) 2005-09-30 2008-08-28 Ilypsa Inc., Santa Clara Verfahren und Zusammensetzungen zum selektiven Entfernen von Kaliumionen aus dem Gastrointestinaltrakt eines Säugers
WO2007038801A2 (fr) 2005-09-30 2007-04-05 Ilypsa, Inc. Compositions de liaison aux cations monovalents comprenant des particules coeur-ecorce avec des ecorces polyvinyliques reticulees et procedes pour les utiliser
CN102600202A (zh) 2005-11-08 2012-07-25 味之素株式会社 麻醉苏醒促进剂
BRPI0618352A2 (pt) 2005-11-08 2011-08-23 Genzyme Corp composições farmacêuticas e métodos de tratamento da hiperfosfatemia em um paciente
ITMI20052461A1 (it) 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
RU2008136081A (ru) 2006-02-14 2010-03-20 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтические составы с алифатическими аминными полимерами и способы их производства
EP2016114A2 (fr) 2006-05-05 2009-01-21 Genzyme Corporation Polymères de condensation d'amines comme agents séquestrants de phosphates
JP2009542653A (ja) 2006-07-05 2009-12-03 ジェンザイム コーポレーション リン酸塩過剰血症のための鉄（ｉｉ）含有治療剤
EP2049014A2 (fr) 2006-07-18 2009-04-22 Genzyme Corporation Dendrimères aminiques
EP2046284A1 (fr) 2006-08-04 2009-04-15 Nastech Pharmaceutical Company Inc. Compositions pour administration intranasale d'insuline humaine et leurs utilisations
EP2064252A2 (fr) 2006-09-01 2009-06-03 Usv Limited Procédé de préparation d'hydrochlorure de sevelamer et formulation de celui-ci
EP2068819A4 (fr) 2006-09-01 2011-04-20 Genzyme Corp Compositions de dendrimères
US7964182B2 (en) 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
WO2008029949A1 (fr) 2006-09-06 2008-03-13 Sucampo Ag Procédé et composition pour favoriser la sécrétion gastro-intestinale du bicarbonate
WO2008042222A2 (fr) 2006-09-29 2008-04-10 Genzyme Corporation Compositions dendrimères d'amide
EP2120972A1 (fr) 2006-12-14 2009-11-25 Genzyme Corporation Compositions de polymère amido-amine
WO2008103368A1 (fr) 2007-02-23 2008-08-28 Genzyme Corporation Compositions de polymère amine
US20080207766A1 (en) 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
WO2008109095A1 (fr) 2007-03-08 2008-09-12 Genzyme Corporation Compositions de polymères de sulfone
TWI445540B (zh) 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
EP2152277A1 (fr) 2007-04-27 2010-02-17 Genzyme Corporation Compositions dendrimères amido-amine
WO2009005838A2 (fr) 2007-07-02 2009-01-08 Cognate3 Llc Procédé de préparation d'une solution basique non corrosive et ses procédés d'utilisation
AU2008273278A1 (en) 2007-07-11 2009-01-15 Toray Industries, Inc. Crosslinked polyallylamine or acid addition salt thereof, and use thereof for medical purposes
EP2016947A1 (fr) * 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Nouveau processus à une étape pour préparer des polymères poly(allylamine) réticulés
WO2009023544A2 (fr) 2007-08-10 2009-02-19 Ilypsa, Inc. Compositions pharmaceutiques à base de polymères échangeurs d'anions en dose
US20090156647A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Method for maintaining physiological pH levels during intensive physical exercise
PA8807201A1 (es) 2007-12-14 2009-07-23 Genzyme Corp Composiciones farmaceuticas
EP2217215A1 (fr) 2007-12-14 2010-08-18 Genzyme Corporation Compositions pharmaceutiques enrobées
WO2009097127A1 (fr) 2008-01-31 2009-08-06 Genzyme Corporation Compositions pharmaceutiques
EP2282729A1 (fr) 2008-03-11 2011-02-16 Livionex Inc. Procédés et compositions pour traiter une inflammation et des pathologies en relation avec une inflammation
US20100331516A1 (en) 2008-04-08 2010-12-30 Govind Dhananjay Sathe Process for Preparation of Sevelamer Carbonate
WO2009154747A1 (fr) 2008-06-20 2009-12-23 Genzyme Corporation Compositions pharmaceutiques
DE102008030046A1 (de) 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
US20100008988A1 (en) 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010022381A1 (fr) 2008-08-22 2010-02-25 Relypsa, Inc. Traitement d'une hyperkaliémie par des polymères d'échange de cation réticulés ayant des propriétés physiques améliorées
WO2010022380A2 (fr) 2008-08-22 2010-02-25 Relypsa, Inc. Compositions de polyfluoroacrylate stabilisé par polyol linéaire
JP2012503642A (ja) 2008-09-25 2012-02-09 バイブ ナノ， インコーポレイテッド ポリマーナノ粒子を製造する方法および活性成分の処方
WO2010035273A2 (fr) 2008-09-29 2010-04-01 Intec Pharma Ltd. Nouveau système de délivrance gastro-rétentif
WO2010059384A1 (fr) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Procédé de préparation de dérivés de pyridine tri-substituée et de pyrimidine tri-substituée utiles comme agonistes du récepteur du peptide insulinotrope glucose-dépendant
US20100166861A1 (en) 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
EP2389168A2 (fr) * 2009-01-22 2011-11-30 USV Limited Compositions pharmaceutiques comprenant un polymère liant le phosphate
CA2777682C (fr) 2009-10-13 2015-02-24 The Regents Of The University Of Michigan Compositions de dendrimeres et procedes de synthese
ES2720869T3 (es) 2009-10-22 2019-07-25 Synthon Bv Composiciones farmacéuticas de sevelámero
RU2012128509A (ru) 2009-12-07 2014-01-20 Айронвуд Фармасьютикалз, Инк. Способы лечения заболеваний желудочно-кишечного тракта
BR112012021448A2 (pt) 2010-02-24 2016-05-31 Relypsa Inc polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina.
BR112012021444A2 (pt) 2010-02-24 2016-05-31 Relypsa Inc polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas.
IT1406068B1 (it) * 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
KR101238210B1 (ko) 2011-06-30 2013-03-04 엘지전자 주식회사 이동 단말기
US20130137772A1 (en) 2011-11-29 2013-05-30 Raymond J. Bergeron Hydroxypolyamine salts
PL3730136T3 (pl) 2012-06-21 2024-03-25 Keryx Biopharmaceuticals, Inc. Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek
JP6475624B2 (ja) 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
ES2834485T3 (es) 2013-06-05 2021-06-17 Tricida Inc Polímeros de unión a protones para administración oral
EP3747432A1 (fr) 2013-11-04 2020-12-09 Keryx Biopharmaceuticals, Inc. Citrate ferrique pour réduire l'insuffisance cardiaque chez des patients souffrant d'une maladie rénale chronique
MA41150B1 (fr) 2014-12-10 2020-06-30 Tricida Inc Polymères de liaison aux protons pour administration orale
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
WO2019090177A1 (fr) 2017-11-03 2019-05-09 Tricida, Inc. Méthode de traitement de troubles de type acide-base
IL273960B2 (en) 2017-11-03 2025-08-01 Tricida Inc Nonabsorable compositions for use in treating or preventing metabolic acidosis
WO2019236639A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement des troubles de l'équilibre acido-basique
MA51628A (fr) 2018-06-04 2021-03-17 Tricida Inc Méthode de traitement de troubles de l'équilibre acido-basique
WO2019236124A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement de troubles de l'équilibre acido-basique
US20200306209A1 (en) 2019-03-27 2020-10-01 Tricida, Inc. Method of treating acid-base disorders

Also Published As

Publication number Publication date
CN109414453B (zh) 2023-02-17
RU2018142943A3 (fr) 2020-08-10
EP3452028A1 (fr) 2019-03-13
IL262660A (en) 2018-12-31
MX2018013476A (es) 2019-03-28
US11992501B2 (en) 2024-05-28
US20190209607A1 (en) 2019-07-11
JP2025157428A (ja) 2025-10-15
US20210205351A1 (en) 2021-07-08
KR20180133931A (ko) 2018-12-17
IL262660B1 (en) 2023-12-01
AU2017261337A1 (en) 2018-11-15
WO2017193050A1 (fr) 2017-11-09
IL262660B2 (en) 2024-04-01
IL308673A (en) 2024-01-01
AU2025217383A1 (en) 2025-09-04
CA3023264A1 (fr) 2017-11-09
AU2023202111A1 (en) 2023-05-04
JP2019514965A (ja) 2019-06-06
US20220062328A1 (en) 2022-03-03
US11406661B2 (en) 2022-08-09
CN116211887A (zh) 2023-06-06
US20190134076A1 (en) 2019-05-09
CN109414453A (zh) 2019-03-01
MA44886A (fr) 2019-03-13
AU2023202111B2 (en) 2025-05-15
JP7071284B2 (ja) 2022-05-18
SG11201809605PA (en) 2018-11-29
JP2022106914A (ja) 2022-07-20
EP3452057A1 (fr) 2019-03-13
WO2017193064A1 (fr) 2017-11-09
MA44875A (fr) 2019-03-13
EP3452028A4 (fr) 2020-04-15
RU2018142943A (ru) 2020-06-08
WO2017193024A1 (fr) 2017-11-09
MY197091A (en) 2023-05-24
US20250009785A1 (en) 2025-01-09
US20200054669A1 (en) 2020-02-20
EP3831395A1 (fr) 2021-06-09
WO2017193024A9 (fr) 2018-11-22
BR112018072714A2 (pt) 2019-02-19
KR102655774B1 (ko) 2024-04-05

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3465212A4 (fr) Régulation du microbiote intestinal pour le traitement de troubles neurodégénératifs
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3400011A4 (fr) Combinaisons anti-cd20 pour le traitement des tumeurs
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA46086A (fr) Schéma posologique pour le traitement de tumeurs solides
EP3506927A4 (fr) Compositions de reeline pour le traitement des troubles neurologiques
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple